The tweet was deleted by the author.
But we saved everything 🙂.
Corbus Pharmaceuticals Holdings, Inc. has appointed Nishant Saxena as its new chief business officer, marking a significant addition to the company’s leadership team.
The firm also announced it will host a conference call and webcast on Tuesday, May 26 at 8 a.m. EDT to present data from its Phase 1/2 study of CRB-701 targeting head and neck squamous cell carcinoma (HNSCC) and cervical cancer. The event is expected to draw attention from investors and analysts ahead of the #ASCO2026 meeting.
Corbus previously announced plans to present updated Phase 1/2 results for CRB-701 at the 2026 ASCO annual meeting, drawing industry interest toward its oncology pipeline developments. The company also recently reported its 2026 first quarter financial results and provided a corporate update. Additional details are available in Corbus’s ASCO event preview and its Q1 financial update.